The Cooper Companies, Inc.

COO Healthcare Medical Instruments & Supplies

The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024.

Revenue
+0.56%
EPS
+357.1%
Free cash flow
+66.0%
Total debt
+2.66%

Quarter to July 2026, against a year earlier

62.61 0.90 −1.42%
Market cap
$12.1B
P/E
21.7×
Fwd P/E
17.5×
Dividend yield
—
F-score
5/9
Altman Z
3.48
Beneish M
−2.50
Dividend safety
n/a

The Cooper Companies, Inc. 10-Q filed Sep 9, 2026

Fiscal Q3 2026 · Period ended Jul 31, 2026 · Filed · accepted 4:48 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jun 5, 2026: 16 added · 4 removed · 24 modified; 10 with only figures updated

  1. Added · CooperVision Net Sales by Category

    In the three months ended July 31, 2026, net sales across all categories were negatively impacted by unfavorable foreign exchange rate fluctuations of approximately $2.8 million, while in the three months ended July 31, 2025, net sales across all categories were positively impacted by favorable foreign exchange rate fluctuations of approximately $26.8 million.